Development and validation of a simple web‐based tool for early prediction of COVID‐19‐associated death in kidney transplant recipients

Modelli de Andrade, Luis Gustavo; de Sandes‐Freitas, Tainá Veras; Requião‐Moura, Lúcio R.; Viana, Laila Almeida; Cristelli, Marina Pontello; Garcia, Valter Duro; Alcântara, Aline Lima Cunha; Esmeraldo, Ronaldo de Matos; Abbud Filho, Mario; Pacheco‐Silva, Alvaro; de Lima Carneiro, Erika Cristina Ribeiro; Manfro, Roberto Ceratti; Costa, Kellen Micheline Alves Henrique; Simão, Denise Rodrigues; de Sousa, Marcos Vinicius; Santana, Viviane Brandão Bandeira de Mello; Noronha, Irene L.; Romão, Elen Almeida; Zanocco, Juliana Aparecida; Arimatea, Gustavo Guilherme Queiroz; De Boni Monteiro de Carvalho, Deise; Tedesco‐Silva, Helio; Medina‐Pestana, José

This analysis, using data from the Brazilian kidney transplant (KT) COVID‐19 study, seeks to develop a prediction score to assist in COVID‐19 risk stratification in KT recipients. In this study, 1379 patients (35 sites) were enrolled, and a machine learning approach was used to fit models in a derivation cohort. A reduced Elastic Net model was selected, and the accuracy to predict the 28‐day fatality after the COVID‐19 diagnosis, assessed by the area under the ROC curve (AUC‐ROC), was confirmed in a validation cohort. The better calibration values were used to build the applicable ImAgeS score. The 28‐day fatality rate was 17% (n = 235), which was associated with increasing age, hypertension and cardiovascular disease, higher body mass index, dyspnea, and use of mycophenolate acid or azathioprine. Higher kidney graft function, longer time of symptoms until COVID‐19 diagnosis, presence of anosmia or coryza, and use of mTOR inhibitor were associated with reduced risk of death. The coefficients of the best model were used to build the predictive score, which achieved an AUC‐ROC of 0.767 (95% CI 0.698–0.834) in the validation cohort. In conclusion, the easily applicable predictive model could assist health care practitioners in identifying non‐hospitalized kidney transplant patients that may require more intensive monitoring. Trial registration: ClinicalTrials.gov NCT04494776.